RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising lymphoma combo trial halted over safety
Disease control OngoingThis study tested a new drug combination (tolinapant plus decitabine/cedazuridine) in 33 people with a rare and aggressive blood cancer called peripheral T-cell lymphoma that had come back or not responded to prior treatment. The goal was to find a safe dose and see if the combin…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for Tough-to-Treat lymphoma: experimental drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests a drug called valemetostat tosylate in people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not improved after other treatments. About 155 adults will take the drug and be monitored for tumor shrinkage and side effects. The go…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 13, 2026 16:01 UTC